Supriya Lifescience Performance dei guadagni passati
Il passato criteri di controllo 4/6
Supriya Lifescience has been growing earnings at an average annual rate of 3.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 6.9% per year. Supriya Lifescience's return on equity is 17.4%, and it has net margins of 25.2%.
Informazioni chiave
3.4%
Tasso di crescita degli utili
1.7%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 17.5% |
| Tasso di crescita dei ricavi | 6.9% |
| Rendimento del capitale proprio | 17.4% |
| Margine netto | 25.2% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Supriya Lifescience (NSE:SUPRIYA) Has Announced That It Will Be Increasing Its Dividend To ₹0.80
Sep 08
We Think You Should Be Aware Of Some Concerning Factors In Supriya Lifescience's (NSE:SUPRIYA) Earnings
Jun 05Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
May 10Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
Feb 09Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
May 28Market Cool On Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings Pushing Shares 27% Lower
May 07Ripartizione dei ricavi e delle spese
Come Supriya Lifescience guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 24 | 6,250 | 1,575 | 931 | 0 |
| 30 Jun 24 | 5,990 | 1,352 | 723 | 0 |
| 31 Mar 24 | 5,704 | 1,191 | 862 | 0 |
| 31 Dec 23 | 5,545 | 1,204 | 832 | 0 |
| 30 Sep 23 | 5,195 | 1,001 | 803 | 0 |
| 30 Jun 23 | 4,916 | 931 | 583 | 0 |
| 31 Mar 23 | 4,609 | 899 | 730 | 0 |
| 31 Dec 22 | 5,069 | 978 | 696 | 0 |
| 30 Sep 22 | 5,188 | 1,280 | 734 | 0 |
| 30 Jun 22 | 5,545 | 1,693 | 534 | 0 |
| 31 Mar 22 | 5,300 | 1,518 | 656 | 0 |
| 31 Dec 21 | 4,754 | 1,543 | 629 | 0 |
| 31 Mar 21 | 3,912 | 1,236 | 501 | 0 |
| 31 Mar 20 | 3,200 | 734 | 345 | 0 |
| 31 Mar 19 | 2,818 | 394 | 261 | 0 |
| 31 Mar 18 | 2,168 | 87 | 230 | 0 |
Guadagni di qualità: SUPRIYA has a high level of non-cash earnings.
Margine di profitto in crescita: SUPRIYA's current net profit margins (25.2%) are higher than last year (19.3%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: SUPRIYA's earnings have grown by 3.4% per year over the past 5 years.
Accelerare la crescita: SUPRIYA's earnings growth over the past year (57.3%) exceeds its 5-year average (3.4% per year).
Guadagni vs Settore: SUPRIYA earnings growth over the past year (57.3%) exceeded the Pharmaceuticals industry 19.1%.
Rendimento del capitale proprio
ROE elevato: SUPRIYA's Return on Equity (17.4%) is considered low.